Clostridium difficile infections in a Shanghai hospital: antimicrobial resistance, toxin profiles and ribotypes

International Journal of Antimicrobial Agents

Volumn 33, Issue 4, 2009, Pages 339-342

  Huang, Haihui ^a,b   Wu, Shi ^a   Wang, Minggui ^a   Zhang, Yingyuan ^a   Fang, Hong ^b   Palmgren, Ann Chatrin ^b   Weintraub, Andrej ^b   Nord, Carl Erik ^b  

^a FUDAN UNIVERSITY   (China)

^b KAROLINSKA INSTITUTE   (Sweden)

Author keywords

Antimicrobial susceptibility; Chinese strains; Clostridium difficile; PCR ribotyping

Indexed keywords

CIPROFLOXACIN; CLINDAMYCIN; DNA TOPOISOMERASE (ATP HYDROLYSING) A; DNA TOPOISOMERASE (ATP HYDROLYSING) B; ERYTHROMYCIN; FUSIDIC ACID; LEVOFLOXACIN; MEROPENEM; METRONIDAZOLE; MOXIFLOXACIN; PIPERACILLIN PLUS TAZOBACTAM; RIFAMPICIN; TETRACYCLINE; VANCOMYCIN;

ANTIBIOTIC RESISTANCE; ARTICLE; BACTERIAL STRAIN; BACTERIUM ISOLATE; CLOSTRIDIUM DIFFICILE; CLOSTRIDIUM DIFFICILE INFECTION; CONTROLLED STUDY; GENE DELETION; GENE MUTATION; INCIDENCE; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; UNIVERSITY HOSPITAL;

ANTI-BACTERIAL AGENTS; BACTERIAL TOXINS; BACTERIAL TYPING TECHNIQUES; CHINA; CLOSTRIDIUM DIFFICILE; CLUSTER ANALYSIS; CROSS INFECTION; DNA GYRASE; DNA, BACTERIAL; DRUG RESISTANCE, BACTERIAL; ENTEROCOLITIS, PSEUDOMEMBRANOUS; GENOTYPE; HOSPITALS, UNIVERSITY; HUMANS; MICROBIAL SENSITIVITY TESTS; MOLECULAR SEQUENCE DATA; RIBOTYPING; SEQUENCE ANALYSIS, DNA;

EID: 61449239004     PISSN: 09248579     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijantimicag.2008.09.022     Document Type: Article

References (26)

1. Loo V.G., Poirier L., Miller M.A., Oughton M., Libman M.D., Michaud S., et al. A predominantly clonal multi-institutional outbreak of Clostridium difficile-associated diarrhea with high morbidity and mortality. N Engl J Med 353 (2005) 2442-2449
2. Katikireddi V. UK launches inquiry into Clostridium difficile outbreak. CMAJ 173 (2005) 138
3. Warny M., Pepin J., Fang A., Killgore G., Thompson A., Brazier J., et al. Toxin production by an emerging strain of Clostridium difficile associated with outbreaks of severe disease in North America and Europe. Lancet 366 (2005) 1079-1084
4. McDonald L.C., Killgore G.E., Thompson A., Owens Jr. R.C., Kazakova S.V., Sambol S.P., et al. An epidemic, toxin gene-variant strain of Clostridium difficile. N Engl J Med 353 (2005) 2433-2441
5. Sawabe E., Kato H., Osawa K., Chida T., Tojo N., Arakawa Y., et al. Molecular analysis of Clostridium difficile at a university teaching hospital in Japan: a shift in the predominant type over a five-year period. Eur J Clin Microbiol Infect Dis 26 (2007) 695-703
6. Kuijper E.J., Coignard B., Tüll P., and ESCMID Study Group for Clostridium difficile; EU Member States; European Centre for Disease Prevention and Control. Emergence of Clostridium difficile-associated disease in North America and Europe. Clin Microbiol Infect 12 Suppl. 6 (2006) 2-18
7. McDonald L.C., Coignard B., Dubberke E., Song X., Horan T., and Kutty P.K. Recommendations for surveillance of Clostridium difficile-associated disease. Infect Control Hosp Epidemiol 28 (2007) 140-145
8. Potvliege C., Labbé M., and Yourassowsky E. Gas-liquid chromatography as screening test for Clostridium difficile. Lancet 318 (1981) 1105
9. Clinical and Laboratory Standards Institute. Methods for antimicrobial susceptibility testing of anaerobic bacteria. 7th ed. Approved standard. Document M11-A7. Wayne, PA: CLSI; 2007.
10. Clinical and Laboratory Standards Institute. Performance standards for antimicrobial susceptibility testing. Sixteenth informational supplement. Document M100-S16. Wayne, PA: CLSI; 2006.
11. Aspevall O., Lundberg A., Burman L.G., Akerlund T., and Svenungsson B. Antimicrobial susceptibility pattern of Clostridium difficile and its relation to PCR ribotypes in a Swedish university hospital. Antimicrob Agents Chemother 50 (2006) 1890-1892
12. Drudy D., Quinn T., O'Mahony R., Kyne L., O'Gaora P., and Fanning S. High-level resistance to moxifloxacin and gatifloxacin associated with a novel mutation in gyrB in toxin-A-negative, toxin-B-positive Clostridium difficile. J Antimicrob Chemother 58 (2006) 1264-1267
13. Stubbs S.L.J., Brazier J.S., O'Neill G.L., and Duerden B.I. PCR targeted to the 16S-23S rRNA gene intergenic spacer region of Clostridium difficile and construction of a library consisting of 116 different PCR ribotypes. J Clin Microbiol 37 (1999) 461-463
14. Kim H., Riley T.V., Kim M., Kim C.K., Yong D., Lee K., et al. Increasing prevalence of toxin A-negative, toxin B-positive isolates of Clostridium difficile in Korea: impact on laboratory diagnosis. J Clin Microbiol 46 (2008) 1116-1117
15. Geric B., Rupnik M., Gerding D., Grabnar M., and Johnson S. Distribution of Clostridium difficile variant toxinotypes and strains with binary toxin genes among clinical isolates in an American hospital. J Med Microbiol 53 (2004) 887-894
16. Gerding D.N., Muto C.A., and Owens Jr. R.C. Treatment of Clostridium difficile infection. Clin Infect Dis 46 Suppl. 1 (2008) S32-42
17. Peláez T., Alcalá L., Alonso R., Rodríguez-Créixems M., García-Lechuz J.M., and Bouza E. Reassessment of Clostridium difficile susceptibility to metronidazole and vancomycin. Antimicrob Agents Chemother 46 (2002) 1647-1650
18. Sánchez-Somolinos M., Alcalá L., Peláez T., Marín M., Martín A., Catalán P., et al. High levels of resistance to fluoroquinolones among Clostridium difficile isolates in a Spanish hospital. Clin Infect Dis 47 (2008) 818-822
19. B) resistance with resistance to moxifloxacin in Clostridium difficile. J Antimicrob Chemother 51 (2003) 599-603
20. Norén T., Wullt M., Akerlund T., Bäck E., Odenholt I., and Burman L.G. Frequent emergence of resistance in Clostridium difficile during treatment of C. difficile-associated diarrhea with fusidic acid. Antimicrob Agents Chemother 50 (2006) 3028-3032
21. Ackermann G., Tang Y.J., Kueper R., Heisig P., Rodloff A.C., Silva Jr. J., et al. Resistance to moxifloxacin in toxigenic Clostridium difficile isolates is associated with mutations in gyrA. Antimicrob Agents Chemother 45 (2001) 2348-2353
22. Dridi L., Tankovic J., Burghoffer B., Barbut F., and Petit J.C. gyrA and gyrB mutations are implicated in cross-resistance to ciprofloxacin and moxifloxacin in Clostridium difficile. Antimicrob Agents Chemother 46 (2002) 3418-3421
23. Peterson M.L., Rotschafer J.C., and Piddock L.J. Plasmid-mediated complementation of gyrA and gyrB in fluoroquinolone-resistant Bacteroides fragilis. J Antimicrob Chemother 52 (2003) 481-484
24. Minnick M.F., Wilson Z.R., Smitherman L.S., and Samuels D.S. gyrA mutations in ciprofloxacin-resistant Bartonella bacilliformis strains obtained in vitro. Antimicrob Agents Chemother 47 (2003) 383-386
25. McFarland L.V. Update on the changing epidemiology of Clostridium difficile-associated disease. Nat Clin Pract Gastroenterol Hepatol 5 (2008) 40-48
26. Goorhuis A., Van der Kooi T., Vaessen N., Dekker F.W., Van den Berg R., Harmanus C., et al. Spread and epidemiology of Clostridium difficile polymerase chain reaction ribotype 027/toxinotype III in The Netherlands. Clin Infect Dis 45 (2007) 695-703